We are a clinical-stage biopharmaceutical company focused on developing transformative genome-edited allogeneic cell therapies for devastating human diseases.
Precision genome editing
Our next-generation CRISPR genome-editing technology enables superior specificity and precision. Our patented chRDNA (CRISPR hybrid RNA-DNA) technology allows for complex genome editing, including multiplex gene knockout and insertion, while maintaining genomic integrity.
Off-the-shelf cell therapies
We are developing allogeneic, or off-the-shelf, CAR-T and CAR-NK cell therapies from healthy donor cells to address the limitations of currently approved therapies.
Armored for antitumor activity
We believe armoring is the key to unlocking the full potential of allogeneic cell therapies. By applying our chRDNA technology and genome-editing strategies, we are developing allogeneic cell therapies armored for potential improvement of antitumor activity.
“Caribou is a leader in the CRISPR field, successfully leveraging its proprietary genome-editing technology to develop allogeneic cell therapies that are potentially transformative for patients.”
Jennifer Doudna, PhD
Co-founder of Caribou
Co-recipient of the 2020 Nobel Prize in Chemistry
Join the Herd
Caribou Biosciences is a pioneer in genome editing and cell therapy development, and we are seeking talented and passionate individuals to join our team.
